Neuroinflammation is a prominent pathological feature of Corticobasal Syndrome (CBS), with distinctive microglial and astrocyte activation patterns that differ from other tauopathies and neurodegenerative diseases. Post-mortem studies and PET imaging using TSPO (translocator protein) ligands have revealed widespread inflammatory responses in CBS brain tissue, particularly in the motor cortex, basal ganglia, and brainstem regions affected by tau pathology [1].
The inflammatory response in CBS involves:
Microglia in CBS exhibit distinct activation patterns compared to other neurodegenerative diseases:
| Feature | CBS | PSP | AD | PD |
|---|---|---|---|---|
| Density increase | High | Moderate | High | Low-Moderate |
| Morphology | Amoeboid | Ramified | Amoeboid | Intermediate |
| Regional focus | Motor cortex | Brainstem | Hippocampus | Substantia nigra |
| TSPO binding | Very high | High | High | Moderate |
TSPO PET studies reveal characteristic patterns in CBS [2]:
Several microglial subtypes have been identified in CBS:
| Cytokine | Level | Source | Function |
|---|---|---|---|
| IL-1β | Elevated | Microglia, astrocytes | Pro-inflammatory, drives tau phosphorylation |
| TNF-α | Elevated | Microglia | Synaptic dysfunction, neuronal death |
| IL-6 | Elevated | Astrocytes | Acute phase response |
| IL-18 | Elevated | Microglia | IFN-γ stimulation |
| TGF-β | Variable | Astrocytes | May be neuroprotective |
The inflammatory environment in CBS promotes tau pathology through [3]:
CBS and PSP share similar inflammatory profiles but differ in:
| Cytokine | CBS | PSP |
|---|---|---|
| IL-1β | +++ | ++ |
| TNF-α | ++ | +++ |
| IL-6 | ++ | + |
| TGF-β | Variable | + |
The complement cascade is heavily activated in CBS [4]:
Complement-mediated synapse elimination in CBS:
| Disease | C1q Deposition | C3 Activation | Synapse Loss |
|---|---|---|---|
| CBS | High | High | Marked |
| PSP | High | High | Moderate |
| AD | Very High | Very High | Severe |
| PD | Low-Moderate | Moderate | Moderate |
Astrocytes in CBS show reactive changes:
| Region | Astrocyte Reactivity | Significance |
|---|---|---|
| Motor cortex | Very high | Core clinical region |
| Basal ganglia | High | Movement dysfunction |
| Brainstem | Moderate | Autonomic features |
| White matter | Moderate | Tract involvement |
Reactive astrocytes in CBS [5]:
CBS and PD share several inflammatory pathways:
| Feature | CBS | Parkinson's Disease |
|---|---|---|
| Primary pathology | 4R tau | α-synuclein |
| Inflammation severity | Very high | Moderate |
| Regional focus | Cortex | Brainstem |
| Astrocyte role | Prominent | Less marked |
| Complement | Central | Secondary |
Understanding these differences informs therapeutic targeting:
| Biomarker | CBS | Changes |
|---|---|---|
| IL-1β | Elevated | Reflects CNS inflammation |
| TNF-α | Elevated | Disease activity |
| C1q | Elevated | Complement activation |
| YKL-40 | Elevated | Astrocyte activation |
| NFL | Elevated | Neurodegeneration |
Targeting neuroinflammation in CBS:
| Target | Approach | Status |
|---|---|---|
| Microglia | Minocycline | Trialed, limited efficacy |
| Cytokines | Anti-IL-1β | Investigational |
| Complement | Anti-C1q | Preclinical |
| TREM2 | Agonists | Development |
Current therapeutic developments targeting neuroinflammation in CBS:
Pardina M, et al. Neuroinflammation in corticobasal degeneration and progressive supranuclear palsy. Acta Neuropathol. 2019. ↩︎
Malpetti M, et al. Microglial activation in corticobasal syndrome: a [11C]PBR28 PET study. Brain. 2020. ↩︎
Sanchez-Guajardo V, et al. Microglia immunophenotyping in corticobasal degeneration. J Neuroinflammation. 2015. ↩︎
Depboylu C, et al. Complement activation in corticobasal degeneration. Brain Pathol. 2012. ↩︎
Escott C, et al. Astrocyte pathology in corticobasal degeneration. Glia. 2021. ↩︎
Rohrer J, et al. The clinical spectrum of corticobasal degeneration. Nat Rev Neurol. 2016. ↩︎
Kahlson C, et al. Microglia: physiological maintenance and activation states. Nat Rev Neurosci. 2022. ↩︎